[Change of blood parameters in liver failure patients with severe hepatitis after combined therapy].
OBJECTIVE
To determine the feasibility, security and clinical effects of the combination of plasma exchange(PE) and high-flow hemodiafiltration (HDF) in the treatment of liver failure caused by severe hepatitis.


METHODS
Fifty-eight treatments with combined therapy were taken in 26 patients with severe hepatitis. The changes of clinical symptom, liver function, plasma thrombinogen activity and ammonia were observed to determine the clinical effects. The feasibility and security were determined by therapy related adverse reactions and tolerance of the patients.


RESULTS
After the treatment, the clinical symptoms such as conscious disturbance, jaundice, inertia, abdominal distention were taken better turn. The serum bilirubin decreased [(190.8+/-93.6) micromol/L] and PTA increased [(19.7+/-8.9)%]. The major adverse reaction was hypersensitive to plasma, no severe hemorrhage, shock and superinfection happened. All patients tolerated the combined therapy.


CONCLUSIONS
The combined therapy is a safe treatment and can significantly improve the symptoms, blood parameters and recently mortality in hepatic failure patients with severe hepatitis. The therapy is worth to spread.
Lin
Jia-hao
JH
The Third Affiliated Hospital of Wenzhou Medical College, Ruian 325200, Zhejiang, China.
Guo
Yan-xue
YX
Zhou
Xiu-hua
XH
Chen
Fang-shu
FS
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D017583:Hemodiafiltration; D006505:Hepatitis / Q000628:therapy*; D006801:Humans; D017093:Liver Failure / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange; D016896:Treatment Outcome